$4.00
+0.06 (+1.52%)
Open$3.98
Previous Close$3.94
Day High$4.25
Day Low$3.96
52W High$14.00
52W Low$3.58
Volume—
Avg Volume58.8K
Market Cap36.29M
P/E Ratio—
EPS$-2.97
SectorBiotechnology
Analyst Ratings
Strong Buy
14 analysts
Price Target
+802.0% upside
Current
$4.00
$4.00
Target
$36.08
$36.08
$23.71
$36.08 avg
$52.26
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 4.00M | 8.74M | 8.70M |
| Net Income | -26,926,304 | -76,794 | -87,592 |
| Profit Margin | -673.1% | -0.9% | -1.0% |
| EBITDA | -28,261,605 | -105,264 | -93,337 |
| Free Cash Flow | — | -51,137 | -57,721 |
| Rev Growth | — | +8.7% | -7.3% |
| Debt/Equity | — | 0.73 | 0.64 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $214.98 | -1.15% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.28 | +0.41% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $140.30 | +0.67% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $447.26 | +0.16% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $777.25 | +0.60% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.73 | -0.65% | 139.7 | 43.84B |